Anti-Fibrosis Effects of Magnesium Lithospermate B in Experimental Pulmonary Fibrosis: By Inhibiting TGF-beta RI/Smad Signaling

doi:10.3390/molecules26061715

	Anti-Fibrosis Effects of Magnesium Lithospermate B in Experimental Pulmonary Fibrosis: By Inhibiting TGF-beta RI/Smad Signaling
	Luo, Xin 1,2; Deng, Qiangqiang 1; Xue, Yaru 1,2; Zhang, Tianwei 1,2; Wu, Zhitao 3; Peng, Huige 1; Xuan, Lijiang 1,2; Pan, Guoyu 1,2
刊名	MOLECULES
	2021-03-01
卷号	26 期号:6 页码:19
关键词	pulmonary fibrosis bleomycin magnesium lithospermate B transforming growth factor-beta Smad signaling
DOI	10.3390/molecules26061715
通讯作者	Xuan, Lijiang(ljxuan@simm.ac.cn) ; Pan, Guoyu(gypan@simm.ac.cn)
英文摘要	Pulmonary fibrosis is a severe and irreversible interstitial pulmonary disease with high mortality and few treatments. Magnesium lithospermate B (MLB) is a hydrosoluble component of Salvia miltiorrhiza and has been reported to have antifibrotic effects in other forms of tissue fibrosis. In this research, we studied the effects of MLB on pulmonary fibrosis and the underlying mechanisms. Our results indicated that MLB treatment (50 mg/kg) for seven days could attenuate bleomycin (BLM)-induced pulmonary fibrosis by reducing the alveolar structure disruption and collagen deposition in the C57 mouse model. MLB was also found to inhibit transforming growth factor-beta (TGF-beta)-stimulated myofibroblastic transdifferentiation of human lung fibroblast cell line (MRC-5) cells and collagen production by human type II alveolar epithelial cell line (A549) cells, mainly by decreasing the expression of TGF-beta receptor I (TGF-beta RI) and regulating the TGF-beta/Smad pathway. Further studies confirmed that the molecular mechanisms of MLB in BLM-induced pulmonary fibrosis mice were similar to those observed in vitro. In summary, our results demonstrated that MLB could alleviate experimental pulmonary fibrosis both in vivo and in vitro, suggesting that MLB has great potential for pulmonary fibrosis treatment.
资助项目	'Organ Reconstruction and Manufacturing' Strategic Priority Research Program of the Chinese Academy of Sciences[XDA16020205] ; National Science Foundation of China[81872927] ; International Partnership Program of Chinese Academy of Sciences[153631KYSB20160004] ; Independent Deployment Program of the Institute of Pharmaceutical Innovation of the Chinese Academy of Sciences[CASIMM0120184005] ; China Postdoctoral Science Foundation[2019M651623]
WOS研究方向	Biochemistry & Molecular Biology ; Chemistry
语种	英语
出版者	MDPI
WOS记录号	WOS:000645435000001
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/296514]
专题	中国科学院上海药物研究所
通讯作者	Xuan, Lijiang; Pan, Guoyu
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 501 Haike Rd, Shanghai 201203, Peoples R China 2.Univ Chinese Acad Sci, Sch Pharm, Beijing 100049, Peoples R China 3.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210033, Peoples R China
推荐引用方式 GB/T 7714	Luo, Xin,Deng, Qiangqiang,Xue, Yaru,et al. Anti-Fibrosis Effects of Magnesium Lithospermate B in Experimental Pulmonary Fibrosis: By Inhibiting TGF-beta RI/Smad Signaling[J]. MOLECULES,2021,26(6):19.
APA	Luo, Xin.,Deng, Qiangqiang.,Xue, Yaru.,Zhang, Tianwei.,Wu, Zhitao.,...&Pan, Guoyu.(2021).Anti-Fibrosis Effects of Magnesium Lithospermate B in Experimental Pulmonary Fibrosis: By Inhibiting TGF-beta RI/Smad Signaling.MOLECULES,26(6),19.
MLA	Luo, Xin,et al."Anti-Fibrosis Effects of Magnesium Lithospermate B in Experimental Pulmonary Fibrosis: By Inhibiting TGF-beta RI/Smad Signaling".MOLECULES 26.6(2021):19.